Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma

Publisher： Karger

E-ISSN： 1423-0232|84|2|123-126

ISSN： 0030-2414

Source： Oncology, Vol.84, Iss.2, 2012-12, pp. : 123-126

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chronically Administered Immunotherapy with Low-Dose IL-2 and IFN-α in Metastatic Renal Cell Carcinoma: A Feasible Option for Patients with a Good Prognostic Profile

By  

Oncology, Vol. 76, Iss. 1, 2008-12 ,pp. : 69-76

Karger

Access to resources Recommend Favorite

Dystonia in a Patient with Melanoma Metastatic to the Brain Treated with High-Dose Interleukin-2, Radiation Therapy, and Levetiracetam

By  

Case Reports in Oncology, Vol. 6, Iss. 1, 2013-01 ,pp. : 78-83

Karger

Access to resources Recommend Favorite

Five-Year Survival Results of Subcutaneous Low-Dose Immunotherapy with Interleukin-2 Alone in Metastatic Renal Cell Cancer Patients

By  

Urologia Internationalis, Vol. 64, Iss. 1, 2000-04 ,pp. : 3-8

Karger

Access to resources Recommend Favorite

Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 3, 2015-09 ,pp. : e1-e5

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial

By  

Oncology, Vol. 88, Iss. 5, 2015-01 ,pp. : 273-280

Karger

Access to resources Recommend Favorite